Desferrioxamine potentiated SOD antiinflammatory activity in rat adjuvant arthritis: Role of iron and bacterial toxins

Benoni, Giuseppina; Cuzzolin, Laura; Zambreri, D.; Caramazza, I.; Soldato, Piero Del; Caliceti, Paolo; Conforti, Anita

doi:10.1007/bf01991042

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As compared to the per-protocol analysis, statistical significance was indeed lost in an intention-to-treat evaluation, which included the subjects who violated the study protocol. Although this may be reasonably explained by the influence of the intercurrent medication taken by these subjects on colonic fermentation and transit time, [36][37][38] it is obvious that our results should be confirmed by larger trials with longer treatment periods. Nevertheless, the data of the present study are of interest as they may provide a rationale for Acarbose treatment in chronic kidney disease patients.…”

Section: Discussionmentioning

confidence: 72%

Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study

Evenepoel

Bammens

Verbeke³

et al. 2006

Kidney International

View full text Add to dashboard Cite

Several protein-bound uremic retention solutes (including p-cresol) originate from colonic bacterial fermentation of protein. Higher colonic availability of carbohydrates drives this process towards lower production of toxic metabolites. Small intestinal alpha-glucosidase inhibitors like Acarbose (Glucobay) enhance the amount of undigested carbohydrates reaching the colon. We studied the effect of Acarbose on generation and serum concentrations of p-cresol. Nine healthy volunteers (age 25 (22-36) years) with a creatinine clearance of 89.6 ml/min/1.73 m(2) (85.5-116.4) were treated with Acarbose for 3 weeks. Dose was gradually increased to reach 300 mg/day after 1 week. Blood sampling, 24-h urine and stool collections on 3 consecutive days were performed before and during the last days of the treatment period. p-Cresol generation was estimated from mean 24-h urinary elimination. Gastrointestinal side effects, if present, were mild to moderate. Serum concentrations of p-cresol declined significantly after Acarbose treatment (before: 1.14 mg/l (0.93-3.03); after: 1.11 mg/l (0.31-1.82); P=0.047). Urinary excretion of p-cresol, reflecting its colonic generation rate, was significantly lower after treatment (before: 29.93 mg/day (6.79-75.19); after: 10.54 mg/day (1.08-30.85); P=0.031). The fecal excretion of nitrogen increased after treatment (before: 1.04 g/day (0.47-2.29); after: 1.99 g/day (0.76-3.08); P=0.047). This pilot study suggests that Acarbose treatment lowers generation and serum concentrations of the protein-bound uremic solute p-cresol. Although further confirmation is warranted, the data may point to a novel treatment option for chronic kidney disease patients in view of the potential toxic effects of p-cresol and related substances.

show abstract

Section: Discussionmentioning

confidence: 72%